Home
ACAD
ACAD News

Latest ACADIA Pharmaceuticals Inc. (ACAD) News on July 7, 2025

MT Newswires

11 days ago

Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $22 From $19, Maintains Perform Rating

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Business Wire

12 days ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Argus Research

12 days ago

ACAD: What does Argus have to say about ACAD?

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital

TipRanks

12 days ago

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital

MT Newswires

14 days ago

RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $26, Keeps Outperform Rating

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent

Insider Monkey

16 days ago

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent

High Growth Tech Stocks In The US Market June 2025

Simply Wall St.

18 days ago

High Growth Tech Stocks In The US Market June 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years

Simply Wall St.

19 days ago

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

19 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication

Insider Monkey

25 days ago

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Business Wire

a month ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Business Wire

a month ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Business Wire

a month ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

Business Wire

a month ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

MT Newswires

2 months ago

Deutsche Bank Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $20

Argus Research

2 months ago

ACAD: Raising target price to $23.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday

Insider Monkey

2 months ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday

Biotech Alert: Searches spiking for these stocks today

TipRanks

2 months ago

Biotech Alert: Searches spiking for these stocks today

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Investor's Business Daily

2 months ago

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

TipRanks

2 months ago

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

TipRanks

2 months ago

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

MT Newswires

2 months ago

Acadia Wins Nuplazid Patent Case in Delaware Court; Shares Surge

Argus Research

2 months ago

ACAD: Raising target price to $18.00

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Zacks

2 months ago

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

Zacks

2 months ago

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

Thomson Reuters StreetEvents

2 months ago

Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call

MT Newswires

2 months ago

Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $20 From $22, Maintains Hold Rating

ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

2 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Associated Press Finance

2 months ago

Acadia: Q1 Earnings Snapshot

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Business Wire

2 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Argus Research

2 months ago

ACAD: What does Argus have to say about ACAD?

US High Growth Tech Stocks To Watch In Your Portfolio

Simply Wall St.

2 months ago

US High Growth Tech Stocks To Watch In Your Portfolio

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Business Wire

2 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Zacks

2 months ago

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

MT Newswires

2 months ago

UBS Adjusts ACADIA Pharmaceuticals Price Target to $22 From $25, Maintains Buy Rating

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Business Wire

2 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Argus Research

2 months ago

ACAD: Lowering target price to $15.00

MT Newswires

3 months ago

BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating

Argus Research

3 months ago

ACAD: Raising target price to $16.00

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

Simply Wall St.

3 months ago

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

3 months ago

ACAD: Lowering target price to $15.00

Argus Research

3 months ago

ACAD: Lowering target price to $17.00

Argus Research

3 months ago

ACAD: What does Argus have to say about ACAD?

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey

3 months ago

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

Insider Monkey

4 months ago

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire

4 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Business Wire

4 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

Zacks

4 months ago

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

Argus Research

4 months ago

ACAD: Lowering target price to $19.00

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

Zacks

4 months ago

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

4 months ago

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Business Wire

4 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

4 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.

4 months ago

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

Business Wire

4 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

GuruFocus.com

4 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

Zacks

4 months ago

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Zacks

4 months ago

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Associated Press Finance

4 months ago

Acadia: Q4 Earnings Snapshot

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Business Wire

4 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Argus Research

4 months ago

ACAD: Lowering target price to $20.00

Argus Research

5 months ago

ACAD: Raising target price to $21.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Zacks

5 months ago

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Business Wire

5 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

MT Newswires

5 months ago

Deutsche Bank Initiates Coverage on ACADIA Pharmaceuticals With Hold Rating, $22 Price Target

High Growth Tech Stocks To Watch In February 2025

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In February 2025

Argus Research

5 months ago

ACAD: Raising target price to $20.00

Argus Research

5 months ago

ACAD: What does Argus have to say about ACAD?

Argus Research

6 months ago

ACAD: Raising target price to $19.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

6 months ago

ACAD: What does Argus have to say about ACAD?

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025

GuruFocus.com

6 months ago

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025

MT Newswires

6 months ago

Acadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

6 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Business Wire

6 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?

Insider Monkey

6 months ago

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%

Simply Wall St.

6 months ago

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%

MT Newswires

6 months ago

Guggenheim Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $20 From $23

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing

Insider Monkey

6 months ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing

MT Newswires

6 months ago

Update: Acadia Pharmaceuticals to Replace Independent Bank in S&P SmallCap 600; Acadia Shares Rise

Acadia Pharmaceuticals Set to Join S&P SmallCap 600

PR Newswire

6 months ago

Acadia Pharmaceuticals Set to Join S&P SmallCap 600

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Business Wire

7 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.

7 months ago

High Growth Tech Stocks To Watch In December 2024

MT Newswires

7 months ago

ACADIA Pharmaceuticals Closes Sale of Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Business Wire

7 months ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Business Wire

7 months ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

Zacks

7 months ago

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options

Zacks

7 months ago

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options

ACAD Signs License Deal With Saniona for Rights to Neurology Drug

Zacks

7 months ago

ACAD Signs License Deal With Saniona for Rights to Neurology Drug

Acadia signs agreement with Saniona to commercialise SAN711

Pharmaceutical Technology

7 months ago

Acadia signs agreement with Saniona to commercialise SAN711

MT Newswires

7 months ago

Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Business Wire

7 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire

8 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks to Watch in November 2024

Simply Wall St.

8 months ago

High Growth Tech Stocks to Watch in November 2024

Share on Social Networks: